摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl (1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylate | 1073118-79-2

中文名称
——
中文别名
——
英文名称
ethyl (1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylate
英文别名
——
ethyl (1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylate化学式
CAS
1073118-79-2
化学式
C36H45N5O6S
mdl
——
分子量
675.849
InChiKey
YHTYQRPEAODVRG-ZVSQVBJESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    48
  • 可旋转键数:
    9
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.53
  • 拓扑面积:
    160
  • 氢给体数:
    2
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl (1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylate 在 lithium hydroxide 作用下, 以 四氢呋喃甲醇 为溶剂, 生成 (1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylic acid
    参考文献:
    名称:
    Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
    摘要:
    SAR analysis performed with a limited set of cyclopentane-containing macrocycles led to the identification of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0(4,6)]octadec-7-ene-4-carbonyl](cyclopropyl) sulfonamide (TMC435350, 32c) as a potent inhibitor of HCV NS3/4A protease (K-i = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies. TMC435350 is currently being evaluated in the clinics. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.07.088
  • 作为产物:
    描述:
    2-(2-异丙基氨基-4-噻唑)-7-甲氧基喹啉-4-醇 、 17-7-(4-bromo-benzensulphonyloxy)-13-methyl-2,1 4-dioxo-3,13-diaza-tricyclo[13.3.0.0*4,6*]octadec-7-ene-4-carboxylic acid ethyl ester 在 caesium carbonate 作用下, 以 N-甲基吡咯烷酮 为溶剂, 生成 ethyl (1R,4R,6S,7Z,15R,17R)-17-[7-methoxy-2-[2-(propan-2-ylamino)-1,3-thiazol-4-yl]quinolin-4-yl]oxy-13-methyl-2,14-dioxo-3,13-diazatricyclo[13.3.0.04,6]octadec-7-ene-4-carboxylate
    参考文献:
    名称:
    Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
    摘要:
    SAR analysis performed with a limited set of cyclopentane-containing macrocycles led to the identification of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0(4,6)]octadec-7-ene-4-carbonyl](cyclopropyl) sulfonamide (TMC435350, 32c) as a potent inhibitor of HCV NS3/4A protease (K-i = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies. TMC435350 is currently being evaluated in the clinics. (C) 2008 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2008.07.088
点击查看最新优质反应信息

文献信息

  • Hcv Ns-3 Serine Protease Inhibitors
    申请人:Rosenquist Asa
    公开号:US20070203072A1
    公开(公告)日:2007-08-30
    Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    本文描述了一种抑制丙型肝炎病毒(HCV)的NS3蛋白酶的肽类类似物化合物。该化合物的化学式中,变量定义如规范中所提供。该化合物包括一个碳环P2单元,与抑制剂更远离天然底物的名义剪切位点的那些部分的新型连接结合,该连接将远侧的肽键方向相对于靠近剪切位点的肽键反转。
  • HCV NS-3 SERINE PROTEASE INHIBITORS
    申请人:Rosenquist Asa
    公开号:US20100166706A1
    公开(公告)日:2010-07-01
    Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    本文描述了用于抑制丙型肝炎病毒(HCV)NS3蛋白酶的肽类类似物化合物的方法。这些化合物的公式为(VI),其中变量定义如规范所述。这些化合物包括一个碳环P2单元,与抑制剂更远离原生底物的部分具有新颖的连接,该连接将远离切割位点的肽键的方向与靠近切割位点的肽键的方向相反。
  • HCV NS-3 serine protease inhibitors
    申请人:Medivir AB
    公开号:US10172846B2
    公开(公告)日:2019-01-08
    Methods drawn to peptidomimetic compounds which inhibit the NS3 protease of the hepatitis C virus (HCV), are described. The compounds have the formula (VI) where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.
    本文介绍了抑制丙型肝炎病毒(HCV)NS3蛋白酶的拟肽化合物的制备方法。这些化合物具有式 (VI),其中变量定义如说明书所提供。这些化合物包括一个碳环 P2 单元,该单元与抑制剂中离原生底物名义裂解位点较远的部分有一种新的连接,这种连接使远端肽键的方向与裂解位点近端的肽键方向相反。
  • US7671032B2
    申请人:——
    公开号:US7671032B2
    公开(公告)日:2010-03-02
  • Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
    作者:Pierre Raboisson、Herman de Kock、Åsa Rosenquist、Magnus Nilsson、Lourdes Salvador-Oden、Tse-I Lin、Natalie Roue、Vladimir Ivanov、Horst Wähling、Kristina Wickström、Elizabeth Hamelink、Michael Edlund、Lotta Vrang、Sandrine Vendeville、Wim Van de Vreken、David McGowan、Abdellah Tahri、Lili Hu、Carlo Boutton、Oliver Lenz、Frederic Delouvroy、Geert Pille、Dominique Surleraux、Piet Wigerinck、Bertil Samuelsson、Kenneth Simmen
    DOI:10.1016/j.bmcl.2008.07.088
    日期:2008.9
    SAR analysis performed with a limited set of cyclopentane-containing macrocycles led to the identification of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.0(4,6)]octadec-7-ene-4-carbonyl](cyclopropyl) sulfonamide (TMC435350, 32c) as a potent inhibitor of HCV NS3/4A protease (K-i = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies. TMC435350 is currently being evaluated in the clinics. (C) 2008 Elsevier Ltd. All rights reserved.
查看更多